Baker McKenzie advised Casdin Capital, an investment firm based in New York and focused on the life sciences and healthcare industry, on the lead of the oversubscribed extension to the Series B fundraising of USD 50 million. Further investors in the Series B extension are Danaher Life Sciences, Agilent Technologies, Merck KGaA, Darmstadt, Germany, M. Ventures, LSP, Bpifrance Large Venture Fund and Illumina Ventures.

The proceeds of the extended Series B will enable DNA Script to accelerate the development of its suite of enzymatic DNA synthesis (EDS) technologies — in particular, to support the commercial launch of the company's SYNTAX™ DNA benchtop printer.

"With a cross-border team of specialised lawyers in the field of biotechnology life sciences, we were able to bring the transaction to a speedy conclusion in close cooperation with our client," comments Berthold Hummel, lead corporate partner in Munich.

Casdin Capital, LLC was founded in 2011 and brings a deep understanding, expertise and long-term perspective to financing the next generation of life science innovation. Specific only to the firm’s diagnostics and molecular information portfolio, Casdin Capital has invested in many of the leading pioneers, including but not limited to Foundation Medicine, Invitae, Adaptive Biotechnologies, Flatiron Health and 23andMe.

Founded in 2014 in Paris, DNA Script is the world’s leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims at accelerating innovation in life sciences and technology through rapid, affordable, and high-quality DNA synthesis. DNA Script’s approach leverages nature's billions of years of evolution in synthesizing DNA to enable genome scale synthesis.

Baker McKenzie's Corporate / M&A and life science team regularly advises big pharma, financial investors and early stage biotech companies on domestic and international healthcare transactions. Most recently, Baker McKenzie advised BioMedPartners on its Series A Equity Financing of € 10.7 million in Tubulis, CureVac on its strategic mRNA technology collaboration with GSK, LSP Life Science Partners on a USD 38.5 Million Series B Financing in DNA Script, listed 4SC AG on a capital increase and international private placement, Galapagos on its 10 year global research and development collaboration with Gilead, MODAG on a € 12 million Series A Financing, Hitachi Chemical Company, Tokyo on the take-over of German apceth Biopharma, Forbion as lead investor on a € 17 million Series C Equity Financing of Omeicos Therapeutics as well as on a USD 54 million Series A Equity Financing of Gotham Therapeutics Corporation, Mundipharma on the sale of its Limburg production, CureVac AG on a collaboration with Eli Lilly and Hillhouse Capital as co-investor in the € 50 million Series C financing of Hookipa Biotech.

Legal advisor to Casdin Capital:
Baker McKenzie

Lead: Corporate/M&A:
Berthold Hummel (partner, Munich)
Gautier Valdiguié (managing associate, Paris)                                                      

Team: Corporate/M&A:
Matthieu Grollemund (partner, Paris)     
Madalina-Georgiana Asandului (associate, Paris)

Guillaume Le Camus (partner, Paris)              
Robin Gaulier (senior associate, Paris)

Jeremie Paubel (partner, Paris)
Roxane Raissi (associate, Paris)

Explore Our Newsroom